Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 5/20 | 0.42 |
| ▸ | EGFR | P00533 | 7/20 | 0.42 |
| ▸ | GSK3B | P49841 | 3/20 | 0.38 |
| ▸ | GSK3A | P49840 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29544947 | 0.97 | TYK2 (0.45) | TYK2EGFRGSK3BGSK3AADORA2A | |
| SCHEMBL29545072 | 0.90 | EGFR (0.42) | TYK2EGFRGSK3BGSK3A | |
| SCHEMBL29545071 | 0.90 | EGFR (0.42) | TYK2EGFRGSK3BGSK3A | |
| SCHEMBL29545545 | 0.87 | EGFR (0.45) | TYK2EGFR | |
| SCHEMBL29544404 | 0.87 | EGFR (0.43) | TYK2EGFR | |
| SCHEMBL29544687 | 0.87 | EGFR (0.43) | TYK2EGFR | |
| SCHEMBL29544823 | 0.87 | EGFR (0.46) | TYK2EGFR | |
| SCHEMBL29545632 | 0.86 | EGFR (0.46) | TYK2EGFR | |
| SCHEMBL29544852 | 0.85 | EGFR (0.49) | EGFR | |
| SCHEMBL29544860 | 0.85 | EGFR (0.49) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022072634-A1 | BICYCLIC COMPOUNDS FOR USE IN THE TREATMENT CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-04-07 | — | — | WO | disclosed |